AlphaQuest’s Phathom Pharmaceuticals PHAT Stock Holding History

AlphaQuest’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-28,250	Closed	-$469K	–	1502
2025 Q4	$469K	Sell	28,250 -26,344	-48%	-$376K	0.03%	882
2025 Q3	$643K	Buy	54,594 +22,388	+70%	+$231K	0.04%	644
2025 Q2	$309K	Buy	32,206 +30,760	+2,127%	+$170K	0.03%	864
2025 Q1	$9.07K	Buy	1,446 +112	+8%	+$680	﹤0.01%	1807
2024 Q4	$10.8K	Sell	1,334 -9,584	-88%	-$119K	﹤0.01%	1467
2024 Q3	$197K	Buy	+10,918	New	+$153K	0.02%	1083
2024 Q1	–	Sell	-2,205	Closed	-$20.1K	–	1767
2023 Q4	$20.1K	Buy	+2,205	New	+$19K	﹤0.01%	965

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

AlphaQuest's PHAT Position: Q1 2026 in Review

AlphaQuest sold out of Phathom Pharmaceuticals (PHAT) in Q1 2026, closing a stake of 28,250 shares — an estimated $469K sold.

AlphaQuest first reported a position in PHAT in Q4 2023 and held it in 7 quarters. The position peaked at $643K in Q3 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

AlphaQuest reported no remaining Phathom Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
AlphaQuest sold 28,250 Phathom Pharmaceuticals shares in Q1 2026, an estimated $469K.
AlphaQuest first reported a position in Phathom Pharmaceuticals in Q4 2023 and held it in 7 quarters.
AlphaQuest's Phathom Pharmaceuticals position peaked at $643K in Q3 2025.
174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.